Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
Increased Cresemba® and Zevtera®-related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidanceOperating profit of CHF 19.2 million.
Adhoc: Spexis AG: Spexis announces closing of sale of preclinical antibiotics program to Basilea finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Spexis AG Key word Miscellaneous Spexis announces closing of sale of preclinical antibiotics program to Basilea 08Feb2024 0715 CETCEST Release of an ad hoc announcement pursuant to Art 53 LR The issu
Basilea Pharmaceutica AG: Cresemba® sales in Latin America trigger first sales milestone payment to Basilea finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.